Formation Bio Lands $372M Series D Amid AI-Driven Expansion
Formation Bio secures $372M Series D led by Sanofi to enhance AI-driven drug development, focusing on workflow automation and AI ...
- Latest
- Trending
Formation Bio secures $372M Series D led by Sanofi to enhance AI-driven drug development, focusing on workflow automation and AI ...
Zealand Pharma's stock surged 17% post-positive trial results for its weight loss drug, showing promising 8.6% average weight reduction. Analysts ...
The stock has dropped 29% in the last year, hitting a low of $11.25 on Oct. 27. A study shows ...
Adial Pharmaceuticals acquires patent for genetic diagnostic tool to identify patients who may respond well to their lead drug AD04, ...
GSK's acquisition of Aiolos Bio expands respiratory treatment options, introducing AIO-001, a promising new treatment for asthma patients.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.